Martin M Bednar Selected Research

ponezumab

4/2019	Immunotherapy with ponezumab for probable cerebral amyloid angiopathy.
9/2017	Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.
9/2017	Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
12/2013	Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.
1/2013	Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
1/2013	Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin M Bednar Research Topics

Disease

14	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 08/2005
5	Dementia (Dementias) 01/2019 - 10/2005
3	Stroke (Strokes) 03/2016 - 04/2002
2	Edema (Dropsy) 04/2019 - 07/2011
2	Headache (Headaches) 09/2017 - 01/2013
2	Cognitive Dysfunction 09/2009 - 08/2005
1	Central Nervous System Diseases (CNS Diseases) 12/2021
1	Kabuki syndrome 12/2021
1	Developmental Disabilities (Developmental Disability) 12/2021
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 04/2019
1	Aphasia (Dysphasia) 04/2019
1	Cerebral Hemorrhage 04/2019
1	Brain Injuries (Brain Injury) 04/2019
1	Subdural Hematoma (Subdural Hemorrhage) 04/2019
1	Ischemic Stroke 03/2016
1	Sensorineural Hearing Loss 07/2015
1	Hypersensitivity (Allergy) 12/2013
1	Lethargy 01/2013
1	Hypesthesia (Numbness) 01/2013
1	Mental Disorders (Mental Disorder) 03/2012
1	Siderosis 07/2011
1	Hernia (Hernias) 01/2010
1	Erectile Dysfunction 07/2008
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2006
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 09/2006
1	Hemorrhage 04/2002

Drug/Important Bio-Agent (IBA)

6	ponezumabIBA 04/2019 - 01/2013
6	Amyloid (Amyloid Fibrils)IBA 04/2019 - 09/2009
3	Monoclonal AntibodiesIBA 09/2017 - 01/2013
1	TAK-418IBA 12/2021
1	Lysine (L-Lysine)FDA Link 12/2021
1	Histones (Histone)IBA 12/2021
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	3- (4- (2- hydroxyethyl)piperazin- 1- yl)- 7- (6- methoxypyridin- 3- yl)- 1- (2- propoxyethyl)pyrido(3,4- b)pyrazin- 2(1H)- oneIBA 03/2016
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 03/2016
1	AcidsIBA 07/2015
1	PF-04958242IBA 07/2015
1	Immunoglobulin G (IgG)IBA 12/2013
1	AntibodiesIBA 12/2013
1	Pharmaceutical PreparationsIBA 01/2013
1	Amyloid beta-PeptidesIBA 01/2013
1	HemosiderinIBA 07/2011
1	Phosphodiesterase 5 InhibitorsIBA 07/2008
1	Sildenafil Citrate (Viagra)FDA Link 07/2008
1	Biological ProductsIBA 09/2006
1	CholesterolIBA 09/2006
1	ApolipoproteinsIBA 09/2006
1	Antihypertensive Agents (Antihypertensives)IBA 09/2006
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2006
1	Nootropic Agents (Nootropics)IBA 10/2005
1	Donepezil (Aricept)FDA LinkGeneric 10/2005
1	Scopolamine (Hyoscine)FDA Link 10/2005
1	Tissue Plasminogen Activator (Alteplase)FDA Link 04/2002
1	Laminin (Merosin)IBA 04/2002
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2002
1	Nitric Oxide Synthase (NO Synthase)IBA 04/2002

Therapy/Procedure

5	Therapeutics 01/2019 - 04/2002
3	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 09/2006 - 08/2005
2	Intravenous Infusions 12/2013 - 01/2013
1	Secondary Prevention 01/2020
1	Immunotherapy 04/2019
1	Local Anesthesia 01/2010
1	General Anesthesia 01/2010
1	Anesthesia 01/2010
1	Thrombolytic Therapy 04/2002
1	Drug Therapy (Chemotherapy) 04/2002